Repository

• Home
• Repository
• Publications

Publications

Efficacy and Toxicity of Pemigatinib in Advanced Cholangiocarcinoma Harboring FGFR Fusions or Rearrangements: A Systematic Review and Meta-analysis Akkus E, Yasar HA, Rimassa L, Lamarca A Target Oncol . 2025 May;20(3):389-403. doi: 10.1007/s11523-025-01142-8 2025  Result from   Funded by

Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials Yoo C, Saborowski A, Hyung J, Wenzel P, Kim I, Wege H, Kim K, Folprecht G, Ryoo B, Schütt P, Cheon J, Götze T, Ryu H, Lee J, Vogel A J Hepatol . 2025 Oct;83(4):909-916. doi: 10.1016/j.jhep.2025.03.013 2025

Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma Macias RIR, Roessler S, Verstegen MMA Hepatology . 2025 Mar 24. doi: 10.1097/HEP.0000000000001322 2025  Result from

Mutational Analysis of Bile Cell-Free DNA in Primary Sclerosing Cholangitis: A Pilot Study Arechederra M, Bik E, Rojo C, Elurbide J, Elizalde M, Kruk B, Krasnodębski M, Pertkiewicz J, Kozieł S, Grąt M, Raszeja-Wyszomirska J, Rullan M, Alkorta-Aranburu G, Oyón D, Fernández-Barrena M, Candels L, Białek A, Krupa Ł, Schneider K, Urman J, Strnad P, Trautwein C, Milkiewicz P, Krawczyk M, Ávila M, Berasain C Liver Int . 2025 Apr;45(4):e70049. doi: 10.1111/liv.70049 2025  Result from

Understanding Cholangiocarcinoma—perspectives from three European advocacy groups Baucells E, Morement H, Leonardi P Lancet Reg Health Eur . 2025 Feb 19:50:101239. doi: 10.1016/j.lanepe.2025.101239 2025  Result from